DrugPatentWatch Database Preview

Details for Patent: 10,065,952

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,065,952 protect, and when does it expire?

Patent 10,065,952 protects INGREZZA and is included in one NDA.

This patent has fifteen patent family members in fifteen countries.

Summary for Patent: 10,065,952

Title:	Valbenazine salts and polymorphs thereof
Abstract:	Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[- 2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.
Inventor(s):	McGee; Kevin (San Diego, CA), Zook; Scott (San Diego, CA), Carr; Andrew (Cambridge, GB), Bonnaud; Thierry (Cambridge, GB)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	15/338,214
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,065,952

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017		RX	Yes	No			Y	Y		TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-002	Oct 4, 2017		RX	Yes	Yes			Y	Y		TREATMENT OF TARDIVE DYSKINESIA

International Family Members for US Patent 10,065,952

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016343633
Brazil	112018008460
Canada	3002074